---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010491"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T21:52:26.383224+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protalix appoints Shmuel Ben Zvi to board; stockholders approve share increase to 144M

## Summary
- Dr. Shmuel Ben Zvi appointed as independent director, joining Audit and Compensation Committees.
- Stockholders approved amendment to increase authorized common shares from 120M to 144M.
- Stockholders approved 2006 Stock Plan amendment raising available shares from ~5.7M to ~8.5M.
- Advisory vote on executive compensation passed with ~80% of votes cast in favor.
- All six director nominees elected; Kesselman & Kesselman ratified as auditor for FY2022.

## SEC filing metadata
- accession: 0001558370-22-010491
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837022010491/0001558370-22-010491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837022010491/plx-20220629x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010491
- JSON: https://secwatch.observer/filing/0001558370-22-010491.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010491.txt

## Key facts
- Executive change
  Shmuel Ben Zvi was appointed as Director at Protalix BioTherapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 29, 2022, the Board of Directors of Protalix BioTherapeutics, Inc. (the "Company") appointed Shmuel Ben Zvi, Ph.D. to serve on the Company’s Board of Directors, effective as of the adjournment of the Company’s 2022 Annual Meeting of Stockholders held on June 30, 2022 (the "Meeting").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837022010491/0001558370-22-010491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.